Tikcro Technologies Reports 2012 Second Quarter Results

Outstanding Note in BioCancell Repaid

Tikcro Technologies Reports 2012 Second Quarter Results

KCSA Strategic Communications212-896-1214 / 1206

Tikcro Technologies Ltd. (OTC PK: TIKRF) today reported results for the second quarter ended June 30, 2012.

Net loss for the second quarter was $124,000, or $0.01 per diluted share. Results for the second quarter included financial expense of approximately $80,000 that resulted from the valuation of Tikcro's holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment. Excluding this non-cash financial expense, net loss for the second quarter was $44,000 or $0.01 per diluted share.

As of June 30, 2012, the Company had net cash totaling $7.0 million.

As of August 1, 2012, Tikcro's note in BioCancell in the principal amount of $2.0 million was repaid in full, including accrued interest, in the total amount of approximately $2.48 million. Total net cash following this repayment is $9.5 million.

Tikcro holds approximately 3.5% of BioCancell's outstanding common stock and approximately 10.5%, when taking into account the exercise of the warrants that Tikcro holds. The common stock of BioCancell is listed on the Tel Aviv Stock Exchange (TASE: BICL).

Tikcro has holdings in BioCancell Therapeutics, Inc., a clinical-stage biopharmaceutical company operating in the area of cancer treatment.

For more information, visit Tikcro website at .

Suggested Articles

Out of options, Tocagen will become Forte Biosciences’ route to the public markets through an all-stock reverse merger.

Reich co-founded Effector and served as its SVP of research but has moved on to take up the CSO position at Turning Point Therapeutics.

BioMarin’s hemophilia A drug has been set an Aug. 21 PDUFA date as the California biotech looks to gain a speedy approval.